Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
94 hedge funds and large institutions have $721M invested in Odonate Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
74% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 23
46% more capital invested
Capital invested by funds: $495M → $721M (+$226M)
39% more call options, than puts
Call options by funds: $3.03M | Put options by funds: $2.18M
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
6% more funds holding
Funds holding: 89 → 94 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.6M |
| 2 |
Morgan Stanley
New York
|
+$8.42M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$6.17M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.26M |
| 5 |
Two Sigma Advisers
New York
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.34M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.42M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.72M |
| 5 |
SCM
Sio Capital Management
New York
|
-$918K |
ODT Hedge Fund Activity: Q4 2020 in Review
94 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q4 2020, worth a combined $721M — up 46% from $495M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ODT positions and 16 closed out — a net gain of 5 holders — while 40 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $10.6M. The largest seller was Wellington Management Group, cutting an estimated $11.8M.
- 94 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q4 2020, up from 89 in Q3 2020.
- Funds reported $721M of Odonate Therapeutics, Inc. Common Stock stock for Q4 2020, up 46% quarter-over-quarter.
- 21 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q4 2020 and 16 closed out, a net change of +5 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q4 2020 was BlackRock, an estimated $10.6M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q4 2020 was Wellington Management Group, an estimated $11.8M sold.
Based on aggregated 13F filings for Q4 2020.